CTI BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana

Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CTI BioPharma Corp. - CTIC

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CTI BioPharma Corp. (NasdaqCM: CTIC) to Swedish Orphan Biovitrum AB ("Sobi"). Under the terms of the proposed transaction, shareholders of CTI will receive only $9.10 in cash for each share of CTI that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([e-mail]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-ctic/ to learn more.

Please note that the merger is structured as a tender offer, such that time may be of the essence.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230510006109/en/

The CTI BioPharma Stock at the time of publication of the news with a raise of +85,27 % to 8,93USD on Nasdaq stock exchange (11. Mai 2023, 02:00 Uhr).